About Deciphex
Deciphex is a company based in Dublin (Ireland) founded in 2017 by Donal O’Shea and Mark Gregson. Deciphex has raised $56.65 million across 13 funding rounds from investors including Novartis, Charles River Laboratories and Enterprise Ireland. Deciphex offers products and services including Patholytix and Diagnexia. Deciphex operates in a competitive market with competitors including PathAI, Viz.ai, Deepcell, Waters Corporation and Pictor Labs, among others.
- Headquarter Dublin, Ireland
- Founders Donal O’Shea, Mark Gregson
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Deciphex Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$56.65 M (USD)
in 13 rounds
-
Latest Funding Round
$17.6 M (USD), Debt – Venture
Oct 02, 2025
-
Investors
Novartis
& 14 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Deciphex
Deciphex offers a comprehensive portfolio of products and services, including Patholytix and Diagnexia.
Enables faster drug testing and accurate diagnostics for pharma companies.
Reduces pathology wait times in healthcare systems like NHS.
Funding Insights of Deciphex
Deciphex has successfully raised a total of $56.65M across 13 strategic funding rounds. The most recent funding activity was a Debt – Venture round of $17.6 million completed in October 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Deciphex
Deciphex has secured backing from 15 investors, including venture fund and institutional investors. Prominent investors backing the company include Novartis, Charles River Laboratories and Enterprise Ireland.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital fund focused on deep tech, consumer tech, health tech, SaaS, and multiple sectors
|
Locked | Locked | Locked | |
|
Early-stage venture capital funding is provided to innovative companies.
|
Locked | Locked | Locked | |
|
Seroba Lifesciences is focused on life sciences venture capital investments.
|
Locked | Locked | Locked |
Investor details for Deciphex
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Deciphex
Investment portfolio details for Deciphex
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Deciphex
Detailed financials for Deciphex
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Deciphex Comparisons
Peer comparison for Deciphex
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Deciphex
Deciphex operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as PathAI, Viz.ai, Deepcell, Waters Corporation and Pictor Labs, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of AI-based solutions for clinical diagnosis of cancer and other diseases
|
|
| Locked | Locked | Locked |
AI and cloud-powered software for stroke care coordination is developed.
|
|
| Locked | Locked | Locked |
AI-powered single cell classification and isolation technology for clinical research
|
|
| Locked | Locked | Locked |
Provider of laboratory management system for researchers and clinicians
|
|
| Locked | Locked | Locked |
AI-based tools for pathological image analysis are provided to labs.
|
Detailed competitors of Deciphex
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Deciphex
Complete news archive for Deciphex
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Deciphex
Deciphex was founded in 2017.
Deciphex is headquartered in Dublin, Ireland.
Donal O’Shea is the current CEO of Deciphex. They have also founded this company.
Deciphex is a funded company, having raised a total of $56.65M across 13 funding rounds to date.
Deciphex was founded in 2017 in Dublin, Ireland, as a provider of digital pathology software. Applications are developed for clinical and veterinary pathology to enhance productivity. Focus is placed on preclinical and toxicologic pathology, where tools assist pathologists in prioritizing critical content. Operations center on software solutions that support diagnostic workflows in the pathology sector.
Deciphex's top competitors include Pictor Labs, PathAI and PAIGE.
Deciphex offers Patholytix and Diagnexia.
Deciphex has 15 investors. Key investors include Novartis, Charles River Laboratories, Enterprise Ireland, European Union, and Molten Ventures.